Posts tagged ‘R&D’

December 23, 2013

Are we dismissing the ‘business’ of clinical research?

Many of us concur that the biopharmaceutical industry is facing a crisis, and that the R&D process needs to transform entirely in order to address skyrocketing costs and minimal effectiveness. While we are starting to see advancements in scientific technologies that address the challenges with early phase research, discussions surrounding the operational and financial aspects of clinical trials do not seem to be addressed frequently. This article will discuss these differences, and address simple and effective ways of reducing R&D costs through effective business models in clinical research.

The rut the biopharmaceutical industry is in

The biopharmaceutical industry is experiencing significant challenges surrounding cost control and strategies in R&D. Figure 1 demonstrates that the amount of capital spent on R&D has continually increased since the 1970s, and has become increasingly volatile since 2004 1, 2. In 2010, the cost of receiving an NME/NBE was $2.35 billion.

See on

From Pharmaceutical Industry digital vision

December 17, 2013

Les laboratoires de R&D veulent plus d’innovations pour en créer de nouvelles | L’Atelier: Disruptive innovation


Pour continuer à penser les innovations de demain, les laboratoires de R&D doivent incorporer les nouvelles solutions numériques en vue de fusionner leurs données.

Alors que les applications mobiles faisant appel au nuage ne cessent de prendre pied dans le commerce et l’industrie, la mise en œuvre des dispositifs mobiles semble également devoir profiter aux projets en laboratoire. “On trouve des applications de géolocalisation, pour traiter les opérations bancaires ou trouver un restaurant ainsi que pour traiter toute sorte de choses à effectuer lorsque l’on est en déplacement. Pourquoi n’y aurait-il pas un besoin pour les scientifiques ?”, s’interroge John Wise, Executive Director de Pistoia Alliance dans l’étude 2014 Forces & Trends publiée par Smartlab. Les travaux de laboratoire demandent en effet des outils de collaboration en situation de mobilité lors des voyages, réunions et colloques et les scientifiques sont particulièrement intéressés par la création d’un flux de travail à travers les applications. Les capacités de traitement de calcul et de stockage des terminaux mobiles seraient en effet parfaitement capables de supporter beaucoup d’applications scientifiques.

Le Cloud et la dématérialisation inexorables

De la même façon que pour le mobile, la montée en force du Cloud doit profiter aux laboratoires de R&D. Ainsi l’étude rappelle que les possibilités de stockage et la puissance de calcul bien supérieures aux capacités d’un PC sont effectivement très attendus par la communauté scientifique. De même la possibilité de prendre des photos avec son appareil mobile pour enrichir les dossiers, d’utiliser des QR Codes pour y accéder, les partager, les archiver, les enrichir d’informations de la communauté scientifique et effectuer les contrôles de qualité constituent des moyens d’organisation améliorateurs. Par ailleurs, les avantages de la transition vers un laboratoire sans papier semblent évidents à Gernot Goeller, Head O&I CoE ED&CMC à Bayer Pharma. “Améliorer le processus d’analyse, accélérer le flux de travail tout en réduisant les coûts sont des bénéfices évidents à condition de gérer les défis d’organisation rencontrés lors de la phase de transition”., déclare-t-il.

See on

From Pharmaceutical Industry digital vision

August 11, 2013

If I Were A Big Pharma Head Of R&D…

The Pharma R&D model is certainly suffering, and the industry’s pandemic sickness is best embodied by “Eroom’s law” of ever-decreasing R&D productivity. But it’s a lot easier to diagnose this disease than it is to prescribe a medicine.

Some of these ideas might be unworkable on a practical basis, but the spirit of where they are trying to steer the R&D organization of the future is clear: a healthier culture that is both more entrepreneurial and empowered to take risks, and less encumbered by legacy baggage and short-termist thinking.

With its deep bench of experienced talent, huge resources, cutting-edge capabilities, and unparalleled global development and downstream footprint, Big Pharma should be well positioned to drive biomedical research and innovation. And there are select examples of that happening today. But collectively as an industry it’s not able to unlock this potential – recoding its cultural DNA may hold the key.

See on

From  Pharmaceutical Industry digital vision

July 8, 2013

Indian pharma shifting R&D overseas : Postnoon


Red tapeism is pushing India’s Rs.1 lakh crore pharmaceutical industry in peril with most of the pharma companies shifting research and development (R&D) operations and clinical trials to South-East Asian countries of Cambodia, Korea, Philippines, Singapore, Thailand, Vietnam and others, according to a just concluded survey by apex industry body Assocham.

“Various South-East Asian countries are wooing India’s R&D industry by offering sops and transparent regulations as regulatory bottlenecks and a plethora of committees have slowed permissions/approvals for trials or marketing drugs to more than 12-15 months back home in India while such permissions are given by the USFDA, EU and Singapore within a month,” says the survey.

The chamber had interacted with about 250 top officials and representatives from India’s pharma industry based out of five states of Andhra Pradesh, Gujarat, Karnataka, Mahara­shtra and Tamil Nadu between March and June 2013 to ascertain and seek solutions to their concerns and problems.

See on

From Pharmaceutical Industry digital vision

Tags: ,